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Abstract 
  
  
Statins are widely used to treat hypercholesterolaemia. However, by inhibiting the production of
mevalonate, they also reduce the production of several isoprenoids that are necessary for the
function of small GTPase oncogenes such as Ras. As such, statins offer an attractive way to inhibit an
“undruggable” target, suggesting that they may be usefully repurposed to treat cancer. However,
despite numerous studies, there is still no consensus whether statins are useful in the oncology
arena. Numerous preclinical studies have provided evidence justifying the evaluation of statins in
cancer patients. Some retrospective studies of patients taking statins to control cholesterol have
identified a reduced risk of cancer mortality. However, prospective clinical studies have mostly not
been successful. We believe that this has occurred because many of the prospective clinical trials
have been poorly designed. Many of these trials have failed to take into account some or all of the
factors identified in preclinical studies that are likely to be necessary for statins to be efficacious. We
suggest an improved trial design which takes these factors into account. Importantly, we suggest
that the design of clinical trials of drugs which are being considered for repurposing should not
assume it is appropriate to use them in the same way as they are used in their original indication.
Rather, such trials deserve to be informed by preclinical studies that are comparable to those for any
novel drug.
Keywords: Statins; Clinical trial design; Drug repurposing
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Preclinical rationale for using statins in cancer patients 
Statins are widely used to treat hypercholesterolaemia. They inhibit hydroxymethylglutaryl 
coenzyme A reductase (HMGCR) which is the rate-limiting step in the synthesis of mevalonate, a 
precursor for the biosynthesis of cholesterol (Fig 1). In addition to their role in controlling 
cholesterol, there is also a solid scientific rationale to consider repurposing statins for use as anti-
cancer agents[1]. Mevalonate also is a precursor for the isoprenoids farnesol and geranylgeraniol 
which are used to post-translationally modify several small GTPase oncogenes (e.g. Ras, Rac, Rho). In 
several cases, this modification has been shown to be necessary for the correct subcellular 
localization of the small GTPases[2].  Consequently, statins provide an elegant way to inhibit these 
oncogenes, which otherwise have been considered by many to be “undruggable”. HMGCR itself is 
recognized as a metabolic oncogene[3], and its expression is increased by gain-of-function variants 
of the commonly mutated tumour suppressor TP53[4].  It is abundantly clear from numerous studies 
from several  groups (reviewed[5]) that, in laboratory studies, statins have desirable anti-cancer 
effects on a broad range of cell lines representing many cancer types. Statins induce G1 cell cycle 
arrest and apoptosis in cancer cells in vitro[5].  Statins may be classified as lipophilic or hydrophilic.  
As anti-cancer agents, lipophilic statins are significantly more potent than hydrophilic ones, 
presumably reflecting their superior membrane permeability[6]. Indeed, one statin which is 
considered to be hydrophilic, pravastatin, is only weakly active against many cancer cell lines.  
Relatively high concentrations of even the lipophilic statins are needed to kill cancer cells but we 
have shown that statins used at these concentrations retain an “on-target” mechanism and affect 
cancer cells through inhibition of HMGCR[7].  
 
Brief summary of the available clinical data 
The widespread use of statins has created a rich source of data to perform retrospective analyses of 
the incidence of cancer and death from cancer in patients using statins to control 
hypercholesterolemia (reviewed[5]). Although some studies have reported a reduction in cancer-
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related mortality among statin users, other studies have found no effect. This is perhaps not 
surprising because the dose and type of statin varies between patients and other factors which 
determine cancer outcome, e.g. health status, may not be adequately balanced between statin users 
and non-users.  Most importantly, these patients have received statins at a dose and frequency that 
is designed to reduce plasma cholesterol, not to have an anti-cancer effect. Thus, it is not clear that 
such studies would detect an anti-cancer effect of statins, even it were present. Controlled 
prospective trials, designed to evaluate an anti-cancer effect, are required. 
 
Table 1 summarizes 27 trials which have prospectively evaluated statins for the treatment of cancer. 
A minority of trials (8/27) included an arm in which the patients received a placebo. The trials have 
evaluated statins across a broad range of cancers, mostly solid tumours but activity in AML and 
multiple myeloma has also been explored.  The majority of trials (19/27) have evaluated simvastatin 
or lovastatin, both of which are lipophilic. Relatively few trials (5/27) evaluated statins as single 
agents. 
 
Two placebo controlled trials[8,9] showed an impressive 8-month increase in survival of patients 
with hepatocellular carcinoma, but the lack of widespread adoption of this into clinical practice over 
the intervening 10 years raises concerns about the validity of these observations.  A further 
encouraging trial found that pravastatin combined with idarubicine and cytarabine led to a 75% 
response rate in relapsed AML with 20 of 26 patient achieving complete remission[10]. Apart from 
these trials, the remaining 23 trials have been significantly less successful and reported at best a 
mixture of partial response or stable disease in a minority of trial subjects. In particular, a recent 
placebo-controlled trial[11] evaluating pravastatin in 410 SCLC patients found no improvement in 
overall survival or progression-free survival. 
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Why have statins not been successful so far? 
These data create a paradox – despite a robust preclinical data and some encouraging clinical 
studies, most prospective studies have been disappointing. We believe that this can be explained by 
three crucial factors that must be considered for the effective use of statins in cancer and that lack 
of consideration of these has led to the unsatisfactory design of many clinical trials.   
 
Dose 
Firstly, the concentration of drug required to cause cell death is significantly higher (10-fold) than 
that achieved in patients following the doses normally used to treat hypercholesterolaemia[12,13], 
suggesting that relatively high statin doses are necessary. This has also been recognized previously 
by several researchers, and 11/27 clinical trials employed a dose of statin that is significantly higher 
than that used to treat hypercholesterolaemia (Table 1). However, the majority of clinical trials 
evaluated a dose of statin that is appropriate to treat hypercholesterolaemia and which affords a 
plasma concentration of statins significantly below that required to induce apoptosis in cancer 
cells[12]. 
 
Schedule and choice of statin 
Secondly, in laboratory studies, we  have found that continual inhibition of HMGCR is necessary to 
induce apoptosis; in vitro, repeated daily cycles of 12 hours simvastatin interspersed with 12 hours 
no-drug did not induce apoptosis, whereas robust cell death was observed if the statin was 
continuously present[12]. This implies that in patients receiving short half-life statins (e.g. 
simvastatin, t½=2-3 hr) once daily, HMGCR activity  would recover between doses allowing 
resynthesis of isoprenoids and reactivation of small GTPases.  A majority of clinical trials have used a 
dosing schedule that we consider to be inappropriate to treat cancer, instead apparently copying the 
schedule designed to treat hypercholesterolaemia. This problem is likely to have arisen in part for 
historical reasons. Lipophilic statins were developed before the hydrophilic ones and although they 
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are more potent in the cancer setting, they have a shorter metabolic half-life in patients due to their 
ready uptake into the liver and subsequent metabolism by cytochrome P450[14].  It is hard to 
conceive how such trials could ever work, now we know continual inhibition of HMGCR is necessary. 
The need to take into account the short half-life of lipophilic statins had been recognized by some 
researchers and 9/27 clinical trials increased the dosing frequency beyond that normally used to 
treat hypercholesterolaemia. A further two trials[15,16] used hydrophilic statins (atorvastatin, 
rosuvastatin) with relatively long half-lives that would improve drug exposure, but as we have noted 
above, these statins are less potent in a cancer setting.  
 
Taking these two factors into account, a lipophilic statin with a relatively long half-life is desirable to  
allow potent and continuous inhibition of HMGCR.  Pitavastatin is the only statin with this 
profile[17]. Its use is approved in the US and EU for hypercholesterolaemia but none of the clinical 
trials have evaluated pitavastatin in oncology.  
 
Diet 
Despite this understanding, our initial study evaluating pitavastatin against ovarian cancer 
xenografts in mice was unsuccessful[13], although others have reported that pitavastatin delayed 
growth of liver, colon and glioblastoma xenografts in mice[18-20].  We, and several others, have 
observed that geranylgeraniol can suppress the pro-apoptotic activity of statins in vitro suggesting 
that inhibition of the production of geranylgeraniol is likely to be essential for the anti-cancer activity 
of statin. This led us to consider whether isoprenoids might be found in mouse chow and human 
food and if this could impact the anti-cancer effect of statins. Solvent extracts of mouse chow, as 
well as human foods (rice, sunflower and olive oil) suppressed the pro-apoptotic activity of 
pitavastatin in vitro[13]. Literature data supports the existence of geranylgeraniol in these 
foods[21,22]. We subsequently found that pitavastatin caused regression of Ovcar-4 xenografts in 
mice maintained on a diet of Ensure Plus (a liquid human food replacement lacking isoprenoids)[13]. 
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Strikingly, supplementation of the Ensure with geranylgeraniol restored tumour growth even though 
the mice still received pitavastatin. This  suggests a third factor crucial to the effective use of statins -  
it may be important to eliminate isoprenoids from patients’ diet. None of the prospective clinical 
trials of statins in cancer limited dietary intake of geranylgeraniol. In fairness, this is understandable 
as all the clinical trials we have assessed were  conducted prior our report of the effects of dietary 
geranylgeraniol. However, it provides a further potential explanation for the failure of prospective 
clinical trials of statins in cancer patients. 
 
Retrospective studies are unable to address these issues  because these assess patients receiving a 
statin in a manner appropriate to control cholesterol, not cancer.  To what extent patients received 
dietary advice which may have inadvertently limited geranylgeraniol is unclear. We suspect that the 
positive retrospective studies reflect an underlying anti-cancer activity of statins, which is more 
easily detected using the relatively large number of patients in these studies, possibly with a 
modified diet. Therefore, we consider it unlikely that retrospective studies will ever be able to 
uncover the full potential of statins in cancer.  In our opinion, many prospective clinical trials of 
statins have been inappropriately designed and no single trial has adequately controlled all the 
variables necessary to evaluate the therapeutic potential for statins in oncology. Thus, there is a 
need for improved prospective clinical trials. 
 
Proposals for the design of clinical trials design to improve the effect of statins in cancer 
We suggest that pitavastatin is the statin most likely to be successful because of its unique 
combination of being both lipophilic and having a longer metabolic half-life. We suggest that clinical 
trials of statins should evaluate high doses of pitavastatin, given twice daily to maintain inhibition of 
HMGCR, while subjects are maintained on a diet which restricts their intake of isoprenoids such as 
geranylgeraniol. It is desirable to identify foods other than Ensure which lack geranylgeraniol to 
facilitate patient compliance with a restricted diet.  It is noteworthy that several of the earlier trials 
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used a design comparable to that which we advocate – relatively high doses of statin administered 
several times during the day. However, these trials did not control diet and it is doubtful whether 
inhibition of HMGCR was maintained overnight because short half-life statins were used. 
 
The high dose of statin we suggest mandates caution. Statins cause myopathy, which in the worst 
case can lead to rhabdomyolysis. Thus, careful dose escalation studies are necessary to determine if 
there is a therapeutic window for pitavastatin. It may also be useful to identify drugs (for example 
bisphosphonates[7,23] or dipyridamole[24])  which could potentially increase the therapeutic 
window by acting synergistically with pitavastatin.  
 
It will also be important to discover predictive biomarkers that identify the patients most likely to 
respond to statins. Gain-of-function mutations in TP53 can increase the expression of HMGCR[4], 
potentially providing one predictive biomarker. In addition, several groups have reported gene 
expression profiles that predict sensitivity to statins in cell culture studies[25-27]. These have 
included genes involved in the mevalonate pathway itself[26-28] and the epithelial-mesenchymal 
transition[25,29,30].  It seems appropriate that clinical trials of statins are designed to allow 
collection of tissue to consolidate these findings, or to identify additional biomarkers 
 
Implications for repurposing of other drugs 
These observations provide guidance for appropriate preclinical studies to assist the design of 
clinical trials for drug repurposing that can be applied to other drugs..  
1. Simply transplanting the dosing regimen used in one disease and hoping that it will be 
applicable to another disease setting seems ill-advised. There is no reason to assume that 
the relationship between pharmacodynamic effect and efficacy is the same in two different 
diseases. In the case of statins, a 50% reduction in plasma cholesterol in low density 
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lipoprotein is clinically meaningful[31], but a similar inhibition of the mevalonate pathway 
may not be sufficient to kill tumour cells. 
2. The dosing schedule that has been developed for treating the original disease may not be 
efficacious in another setting. Short half-life statins are effective at reducing plasma 
cholesterol if taken in the evening, because most cholesterol synthesis takes place 
overnight[32],  but it is not clear that there is a similar pattern of geranylgeraniol synthesis in 
tumour cells. Preclinical studies to understand the relationship between exposure and 
efficacy in the new disease are essential to guide clinical trial design. 
3. Different drugs from the same drug class may be behave similarly in one disease but 
differently in another. The differences in the pharmacodynamic and exposure requirements 
for efficacy between two diseases means that different drugs, even from the same drug 
class, may behave very differently in the new disease setting. For example, differences in 
half-lives or potencies between drugs may play a crucial role in determining whether they 
are efficacious in the new setting. In the case of statins, lipophilicity and a long half-life seem 
more important in oncology than in treating cardiovascular disease. 
4. The patient population that will benefit from the repurposed drug needs to be defined. 
Statins are effective in the majority of patients with hypercholesterolaemia[33], but it does 
not necessarily follow that the majority of cancers are necessarily dependent on the 
mevalonate pathway.  
5. There may be additional factors that affect the safety and efficacy of the drug in the new 
disease. For example, the supply of dietary geranylgeraniol may not impact the effect of 
statins on plasma cholesterol but it is likely to crucially affect their efficacy against cancer. 
Preclinical studies to identify such factors are appropriate prior to clinical trials. In the case 
of drugs which target metabolic processes, it seems sensible to evaluate the impact of diet 
on efficacy/safety and how this may be controlled in clinical trials. 
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We conclude that trials with statins in oncology have mostly been inadequately designed and the 
question whether statins are useful in the treatment of cancer remains to be properly addressed. 
We consider pitavastatin to be the statin most likely to be effective in cancer and appropriately 
designed clinical trials, following the guidelines we propose, are needed. In general, when drugs are 
being considered for repurposing, preclinical studies to understand how to use the drug are critical 
to support the diligent design of clinical trials. 
 
 
 
 
 
Figure 1 Legend. 
Figure 1. The mevalonate pathway. Statins inhibit the synthesis of cholesterol as well as isoprenoids 
needed for the function of several small GTPase oncogenes. 
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Cancer 
type 
Statin Concurrent 
therapy 
Statin 
dose 
Statin 
schedule 
# 
patients 
Response Ref 
Various Lovasta
tin 
N/A 2 to 45 
mg/kg/da
y 
4 x per 
day,  
monthly 
cycles of 
7 days 
dosing 
56 1 PR (2%) [34] 
Various Fluvasta
tin  
N/A 2 to 8 
mg/kg/da
y 
1 x per 
day, 
monthly 
cycles of 
14 days 
drug, 
12 2 PR 
(17%) 
[35] 
Gastric  Lovasta
tin 
N/A 35 
mg/kg/da
y 
Split 
across 4x 
per day, 
7 days, 
monthly 
cycles 
14 1 SD (7%) [36] 
Hepatocel
lular 
carcinom
a 
Pravast
atin 
Prior TAE + 5FU 0 or 40 
mg 
1 x per 
day for  
16 
months 
41 statin, 
42 
placebo 
OS 19 
months 
(Pravasta
tin) v 9 
months 
(placebo) 
P=0.006 
[8] 
Head and 
neck 
squamou
s cell 
carcinom
a 
Lovasta
tin 
N/A 5 to 
7.5mg/kg
/day 
Explored 
several 
up to 
cycles of 
21 days 
on, 7 
days off,  
split 
across 4 x 
per day 
22 6 SD 
(27%) 
[37] 
Various Lovasta
tin 
N/A 10 to 
415mg/m
2 
Every 6h, 
for 4 
days, 24 
days off, 
1-6 cycles 
32 4 SD 
(13%) 
[38] 
Myeloma, 
lymphom
a 
Simvast
atin 
Vincristine, 
doxorubicin, 
dexamethasone 
or 
cyclophosphami
de, vincristine, 
doxorubicin, 
5 to  15 
mg/kg/da
y 
Spilt 
across 2 
doses for 
7 days, 
prior to 
chemoth
erapy 
28 
 
 
1 CR 
(4%), 3 
PR (11%), 
3 MR 
(3%), 5 
SD (18%) 
[39] 
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prednisolone. 
Myeloma, 
lymphom
a 
Simvast
atin 
Vincristine, 
doxorubicin, 
dexamethasone 
15 
mg/kg/da
y 
Spilt 
across 2 
doses, 2-
4 cycles 
of 7 days 
on, 21 
days off 
12 1 PR 
(8%), 6 
SD (50%) 
[40] 
Multuiple 
myeloma 
(chemoth
erapy 
resistant) 
Simvast
atin 
Bortezomib, 
bendamustine 
80 
mg/day 
Once 
daily,  5 
days 
6 5/6  
(83%) 
show 
decrease
d 
paraprot
ein 
[41] 
Gastric Pravast
atin 
TACE 0 or 20-
40 
mg/day 
Once 
daily 
131 TACE 
only 52 
TACE & 
pravastat
in 
Increased 
OS 20.9  
months 
(statin) 
versus 12 
months 
(placebo) 
P=0.003 
[9] 
Brain 
stem 
tumours 
Fluvasta
tin  
Carboplatin, 
vincristine, 
thalidomide; 
radiotherapy 
8mg/kg/
day 
1 x per 
day, 4 
cycles  of 
28 days 
with 
statin 
days 1-14 
9 7 PR 
(78%) 
[42] 
Multiple 
myeloma 
Simvast
atin 
Various 15 
mg/kg/da
y 
Split 
across 2 
doses, 2 
cycles of 
7days 
drug +21 
days off 
6 Study 
terminate
d early 
due to 
osteoclas
t activity 
[43] 
Colorectal Simvast
atin 
Irinotecan, 5FU, 
leucovorin 
40 
mg/day 
Once 
daily 
49 Response 
rate 
compara
ble to 
historical 
studies of 
chemoth
erapy 
alone 
[44] 
Gastric Pravast
atin 
Epirubicin, 
capecitabine, 
cisplatin 
0 or 40 
mg/day 
Once 
daily 
14 statin, 
14 
placebo 
Response 
rate not 
increased 
by statin, 
study 
[45] 
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terminate
d before 
further 
accrual 
Non-small 
cell lung 
cancer 
Simvast
atin 
Gefitinib 40 
mg/day 
Once 
daily 
54 
gefitinib 
& 
simvastat
in, 
52 
gefitinb 
only 
OS 13.6 
months 
(gefitinib 
& 
simvastat
in) v 12 
months 
(gefitinib 
alone), 
P>0.05 
[46] 
Non-small 
cell lung 
cancer 
Simvast
atin 
Irinotecan, 
cisplatin 
40 
mg/day 
Once 
daily 
56 42 PR 
(75%), 10 
SD (18%) 
- not 
different 
to 
historical 
data 
[47] 
Pancreati
c 
Simvast
atin 
Gemcitabine 0 or 
40mg/da
y 
Once 
daily 
58 
gemcitab
ine & 
simvastat
in 
 56 
gemcitab
ine 
1 year OS 
27%  
(gemcitab
ine & 
simvastat
in),  OS 
20% 
(gemcitab
ine alone) 
P>0.05 
[48] 
Colorectal 
(Kras 
mutant) 
Simvast
atin 
Cetuximab, 
irinotecan 
80 
mg/day 
Once 
daily 
47 1 PR 
(2%), 33 
SD (70%) 
[49] 
Acute 
myeloid 
leukemia 
Pravast
atin 
Idarubicine, 
cytarabine 
1280 
mg/day 
Once 
daily 
36 20 CR 
(56%), 7 
CRi 
(19%), 
significan
tly 
different 
from 
historical 
data 
P<0.05 
[10] 
Gastric Simvast
atin 
Capecitaine, 
cisplatin 
0 or 40 
mg/day 
Once 
daily 
120 
statin, 
124 
placebo 
1 year 
survival 
47.9 m 
(simavast
atin) vs 
[50] 
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47.7 m 
(placebo) 
MDS Atorvas
tatin 
Idarubicin, 
cytarabine 
1280 
mg/day 
Once 
daily 
24 15 CR 
(63%), 
but didn’t 
meet 
70% CR 
rate 
criteria to 
continue 
study. 
[16] 
Colorectal 
(Kras 
mutant) 
Simvast
atin 
Panitumumab  Once 
daily 
14 1 (7%) 
patient 
durable 
PFS but 
didn’t 
meet 
criteria to 
continue 
study. 
[51] 
Colorectal Simvast
atin 
Irinitecan, 
leucovorin, 5FU 
or irinotecan, 
capecitabine 
0 or 40 
mg/day 
Once 
daily 
134 
statin, 
135 
placebo 
OS 15.9 
m 
(simvasta
tin), 19.9 
m 
(placebo), 
P>0.05 
[52] 
Colorectal 
(Kras 
mutant) 
Simvast
atin 
Cetuximab 80 
mg/day 
Once 
daily 
18 4 (22%) 
increased  
PFS but 
didn’t 
meet 
criteria to 
continue 
study 
[53] 
Various Rosuvas
tatin 
Erlotinib 1- 2 
mg/kg/da
y 
Statin 
given 
daily 2 or 
3 weeks; 
dose 
divided 
between 
and 4 
times 
according 
to dose 
level.  
22 4 (18%) 
SD 
[15] 
Brain 
metastas
es from 
various 
Simvast
atin 
Radiation 0 or 80 
mg/day 
Once 
daily 
50 1 year 
survival 8 
% 
(statin),  
[54] 
  
20 
 
tissue vs 12% 
(control)  
P > 0.05 
Small cell 
lung 
cancer 
Pravast
atin 
Etoposide + 
cisplatin or 
carboplatin 
radiotherapy 
40 
mg/day  
Once 
daily 
410 
statin, 
409 
placebo 
OS 10.7 
m 
(statin), 
10.6 m 
(placebo) 
[11] 
 
Table 1 A search of Pubmed for clinical trials containing the terms “statin” and “cancer” led to the 
identification of 27 reports. The table summarizes the type of cancer in which the statin was 
evaluated, the dosing regimen of the statin and the outcome. Trials which included a placebo arm 
are those in which dose is also reported as 0 mg/day.  CR, complete response; PR, partial response; 
SD, stable disease; OS, overall survival; PFS, progression-free survival, TACE, transarterial 
chemoembolization. 
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Highlights 
 Significant preclinical and retrospective clinical studies suggest statins are effective in cancer 
but prospective trials have failed 
 Statin type, dose, dose interval, and patient diet have not been adequately considered  
 An improved trial design for statins in cancer is proposed 
 Clinical trial design during drug repurposing studies needs careful consideration. 
 
